A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

BACKGROUND: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition. A first-in-human trial evaluating tolerability, pharmacokinet...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Mateo, Joaquin, Olmos, David, Dumez, Herlinde, Poondru, Srinivasu, Samberg, Nancy L, Barr, Sharon, Van Tornout, Jan M, Jie, Fei, Sandhu, Shahneen, Tan, Daniel S, Moreno, Victor, LoRusso, Patricia M, Kaye, Stan B, Schöffski, Patrick
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2016
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984800/
https://ncbi.nlm.nih.gov/pubmed/27002938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.59
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi